IS5572A - Orkuríkar sýklódextrínfléttur - Google Patents

Orkuríkar sýklódextrínfléttur

Info

Publication number
IS5572A
IS5572A IS5572A IS5572A IS5572A IS 5572 A IS5572 A IS 5572A IS 5572 A IS5572 A IS 5572A IS 5572 A IS5572 A IS 5572A IS 5572 A IS5572 A IS 5572A
Authority
IS
Iceland
Prior art keywords
rich
energy
cyclodextrin complexes
cyclodextrin
complexes
Prior art date
Application number
IS5572A
Other languages
English (en)
Icelandic (is)
Inventor
Loftsson Thorsteinn
βr M βsson M
Stef βnsson Einar
Original Assignee
Cyclops Ehf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclops Ehf. filed Critical Cyclops Ehf.
Publication of IS5572A publication Critical patent/IS5572A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5572A 1998-02-23 2000-07-25 Orkuríkar sýklódextrínfléttur IS5572A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7554498P 1998-02-23 1998-02-23
PCT/IS1999/000003 WO1999042111A1 (en) 1998-02-23 1999-02-16 High-energy cyclodextrin complexes

Publications (1)

Publication Number Publication Date
IS5572A true IS5572A (is) 2000-08-16

Family

ID=22126450

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5572A IS5572A (is) 1998-02-23 2000-07-25 Orkuríkar sýklódextrínfléttur

Country Status (7)

Country Link
EP (1) EP1067942A1 (xx)
JP (1) JP2003522207A (xx)
AU (1) AU759280C (xx)
CA (1) CA2320772A1 (xx)
IS (1) IS5572A (xx)
NZ (1) NZ505951A (xx)
WO (1) WO1999042111A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7937500A (en) * 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
DE60115217T2 (de) * 2000-03-28 2006-07-20 Farmarc Nederland B.V. Alprazolam inklusion-komplexe und ihre pharmazeutischen zusammensetzungen
CN100391462C (zh) 2001-06-18 2008-06-04 诺芬药品公司 增强的透皮给药系统
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
WO2003022270A1 (en) * 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Transdermal administration of an enalapril ester
ES2301807T3 (es) * 2002-06-13 2008-07-01 Novartis Ag Compuestos de amoniociclodextrina cuaternizados.
RS20050735A (xx) 2003-03-28 2008-06-05 Ares Trading S.A., Formulacije kladribina za poboljšanu oralnu i transmukoznu primenu
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
NZ548225A (en) 2003-12-31 2012-12-21 Cydex Pharmaceuticals Inc Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
WO2007050075A1 (en) 2005-10-26 2007-05-03 Cydex, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EA200900571A1 (ru) * 2006-10-20 2009-12-30 Айкос Корпорейшн Композиции chk1 ингибиторов
US20100056500A1 (en) * 2006-11-21 2010-03-04 Thitiwan Buranachokaisan Stable Parenteral Formulation
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010076112A2 (en) 2008-12-29 2010-07-08 Unilever Plc Food products enriched with methylxanthines
KR20190071006A (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CA2798911C (en) 2010-05-19 2018-07-03 Unilever Plc Theobromine for increasing hdl-cholesterol
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
CN104704007A (zh) 2012-02-28 2015-06-10 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN104870001B (zh) 2012-11-15 2019-01-18 赛博尔泰克股份公司 用作消炎或免疫抑制有效成分的飞燕草素络合物
US9511047B2 (en) 2012-12-11 2016-12-06 Sapiotec Gmbh Delphinidin for combating melanoma cells
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation

Also Published As

Publication number Publication date
JP2003522207A (ja) 2003-07-22
WO1999042111A1 (en) 1999-08-26
EP1067942A1 (en) 2001-01-17
CA2320772A1 (en) 1999-08-26
AU2638599A (en) 1999-09-06
AU759280B2 (en) 2003-04-10
AU759280C (en) 2004-01-22
NZ505951A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
IS5572A (is) Orkuríkar sýklódextrínfléttur
DK1075281T3 (da) Polyol-IFN-beta-konjugater
DE69932980D1 (de) Resolversignalverarbeitungssystem
NO20010193L (no) Tiobenzimidazol-derivater
DK0930302T3 (da) Benzosulfonderivater
NO994875D0 (no) Forbundne metallkomplekser
ATE259810T1 (de) Phenyl-xanthinderivate
NO20010514D0 (no) Aminometylkarboksylsyre-derivater
DE59907315D1 (de) Fahrzeugrechneranordnung
ATE234316T1 (de) Metallocenkomplexe
DE69902762T2 (de) Riser-spannanordnung
DE69925655D1 (de) Rückleuchte
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
ATE233253T1 (de) Chromanderivate
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
DK1060183T3 (da) 5-deoxycytidinderivater
FI980759A0 (fi) Taetningskonstruktion foer suglaodan i en sugvals
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate
SE9901098L (sv) Fördelarlåda
DE59807199D1 (de) Zerspaner
FIU980508U0 (fi) Puukuitulevy
UA2866S (uk) Втулка
FI4121U1 (fi) Poikittaiskuljetin
DK199800333U3 (da) Kombinationsprodukt
SE9902890D0 (sv) Golvrelaterat arrangemang